Evaluation and Management of Thrombocytosis

Risk Stratification

The National Comprehensive Cancer Network recommends that risk assessment for thrombocytosis should be based on age, with patients under 60 years old considered lower risk 1, 3
The presence of a prior history of thrombosis is a significant risk factor, with its absence being favorable 1, 4
A platelet count greater than 1,000 × 10^9/L is associated with bleeding risk rather than thrombosis 1, 3
The JAK2 mutation status is also a factor, with the absence of the mutation being favorable 2, 4

For patients with a platelet count less than 1,000 × 10^9/L, observation is appropriate without cytoreductive therapy, according to the National Comprehensive Cancer Network 1, 2
If the platelet count exceeds 1,000 × 10^9/L, further evaluation for bleeding risk due to acquired von Willebrand disease should be considered 1, 3
The American College of Physicians and other guideline societies recommend aggressively managing cardiovascular risk factors if present 4
Low-dose aspirin therapy may be considered if vascular symptoms are present, as suggested by the National Comprehensive Cancer Network 2

Periodic monitoring of platelet counts every 3-6 months is recommended to assess for progression, according to the National Comprehensive Cancer Network 2
Further investigation is warranted if the platelet count exceeds 1,000 × 10^9/L, or if there is a progressive increase in platelet count over time, or if symptoms such as headaches or visual disturbances develop 1, 2, 3, 5